Business
Gain Therapeutics Announces Oral Presentation at 2nd GBA1 Meeting
BETHESDA, Md., May 29, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced an oral presentation at the GBA1 Meeting 2025, being held June 5th-7th in Montreal, Canada. Details of the oral presentation are as follows: Date: Thursday, June 5, 2025 Time: 11:20 p.m. EST Presenter: Jonas Hannestad, M.D., Ph.D
About this update from Gain Therapeutics, Inc.
[{"type":"image","alt":"Gain Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Gain Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":150,"height":72,"url":"https://media.zenfs.com/en/globenewswire.com/71d53e58a7e975cfd00a1328d22e0699"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/nsPBXqjXYfLs4XgIgz1iUg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTEwMTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/71d53e58a7e975cfd00a1328d22e0699","width":150,"height":72}},"lazy":false},{"type":"text","content":"BETHESDA, Md., May 29, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced an oral presentation at the GBA1 Meeting 2025, being held June 5th-7th in Montreal, Canada.","length":362,"tagName":"p"},{"type":"text","content":"Details of the oral presentation are as follows:","length":48,"tagName":"p"},{"type":"text","content":"Date: Thursday, June 5, 2025","length":28,"tagName":"p"},{"type":"text","content":"Time: 11:20 p.m. EST","length":20,"tagName":"p"},{"type":"text","content":"Presenter: Jonas Hannestad, M.D., Ph.D., Chief Medical Officer, Gain Therapeutics","length":81,"tagName":"p"},{"type":"text","content":"About Gain Therapeutics, Inc.Gain Therapeutics, Inc. is a clinical-stage biotechnology company leading the discovery and development of next generation allosteric therapies. Gain’s lead drug candidate, GT-02287 is currently being evaluated for the treatment of Parkinson’s disease with or without a GBA1 mutation in a Phase 1b clinical trial. GT-02287 has further potential in Gaucher’s disease, dementia with Lewy bodies, and Alzheimer’s disease. Gain has multiple undisclosed preclinical assets targeting lysosomal storage disorders, metabolic diseases, and solid tumors.","length":574,"tagName":"p"},{"type":"text","content":"Gain’s unique approach enables the discovery of novel, allosteric small molecule modulators that can restore or disrupt protein function. Deploying its highly advanced Magellan™ platform, Gain is accelerating drug discovery and unlocking novel disease-modifying treatments for untreatable or difficult-to-treat disorders including neurodegenerative diseases, rare genetic disorders and onco...